
Health technology companies, clinicians and patient groups have until Monday, October 19, 2026, to share their views on the US Food and Drug Administration’s proposed approach to generative artificial intelligence in medical devices.
The FDA published a discussion paper in August 2026 seeking feedback on a risk-proportionate approach to regulating software that uses generative AI, including systems that operate with some autonomy.
The comment window is an opportunity for interested parties to explain how the proposed approach could affect their work and to offer evidence-based suggestions.
What Is the FDA Asking for?
The FDA’s discussion paper concerns the regulation of generative AI used in medical devices.
The paper explores a risk-proportionate approach, meaning that the regulatory approach would consider the nature and level of risk associated with the technology. The supplied information also notes that the discussion includes systems with some degree of autonomy.
Because the document is a discussion paper, it should not be described as a final rule. The purpose of the comment process is to gather feedback on the agency’s proposed approach.
The supplied information gives August 15 and August 18 as possible publication dates for the discussion paper. The exact date should be confirmed against the official FDA announcement.
Who Can Submit a Comment?
The opportunity is not limited to medical technology companies. According to the supplied information, anyone can submit a comment.
Potential contributors include:
- Health technology companies developing generative AI medical software.
- Clinicians who use or work with medical technology.
- Patient groups interested in the safety and performance of healthcare tools.
- Other interested individuals and organisations.
Comments can be submitted through Regulations.gov under docket FDA-2026-N-7874, according to the supplied details.
Before submitting, contributors should check the official docket for the deadline, submission instructions and any relevant requirements.
What Should a Useful Comment Include?
A useful comment should respond to the proposal directly rather than offering only general approval or disagreement.
The supplied information recommends identifying the specific section being addressed, explaining who is submitting the comment and describing how the proposal could affect them. It also recommends providing evidence or a concrete alternative where possible.
For developers of clinical or patient-facing AI tools, the discussion paper raises questions about demonstrating a product’s competency and monitoring its performance after it reaches the market.
A comment can be more useful when it explains a practical issue, gives supporting evidence and proposes a clear alternative or improvement.
Why AI Medical Device Oversight Matters
Generative AI in healthcare raises questions about how software performance should be evaluated and monitored. The FDA’s discussion paper focuses on how its approach should account for the risks associated with these technologies.
The supplied information also refers to a wider FDA focus on AI oversight, including an earlier warning letter to a pharmaceutical company over the use of AI without adequate human oversight and a pilot designed to collect clinical trial safety signals in real time.
Those examples form part of the broader context, but the details of the warning letter and pilot should be verified before publication.
Compliance Costs and Proposed Requirements
One trade publication, Daily AI World, warned that compliance costs could rise significantly because of proposed logging and validation requirements.
That assessment should be presented as the publication’s interpretation, not as an established outcome. The document is a discussion paper, and the supplied information does not establish that the described requirements have become final rules.
Companies assessing the potential impact should distinguish between proposals under discussion and requirements that have formally taken effect.
What Happens Before the Deadline?
The stated deadline is Monday, October 19, 2026. Anyone planning to submit should review the official docket and prepare their comment before the final day.
The deadline and submission instructions should be confirmed directly on Regulations.gov, particularly because the supplied information notes that the docket page could not be opened during the initial research.
The FDA’s comment window gives health technology companies, clinicians, patient groups and other interested parties an opportunity to respond to its proposed approach to generative AI in medical devices.
For those planning to comment, the strongest contribution is likely to be one that addresses a specific part of the discussion paper, explains the practical impact and supports its recommendations with evidence.




